Serotonin 6 receptor controls alzheimer’s disease and depression
Open accessAbstract
// Hyung-Mun Yun 1,* , Kyung-Ran Park 2,* , Eun-Cheol Kim 1 , Sanghyeon Kim 4 and Jin Tae Hong 3 1 Department of Maxillofacial Tissue Regeneration, School of Dentistry and Research Center for Tooth and Periodontal Regeneration (MRC), Kyung Hee University, Seoul, Republic of Korea 2 Department of Oral & Maxillofacial Regeneration, Kyung Hee University, Seoul, Republic of Korea 3 College of Pharmacy and Medical Research Center, Chungbuk National University, Chungbuk, Republic of Korea 4 Stanley Brain Research Laboratory, Stanley Medical Research Institute, Rockville, MD, USA * These authors have contributed equally to this work Correspondence to: Jin Tae Hong, email: // Sanghyeon Kim, email: // Keywords : 5-HT6R, serotonin, APBA1/2, alzheimer’s disease, depression Received : August 19, 2015 Accepted : August 29, 2015 Published : September 22, 2015 Abstract Alzheimer’s disease (AD) and depression in late life are one of the most severe health problems in the world disorders. Serotonin 6 receptor (5-HT 6 R) has caused much interest for potential roles in AD and depression. However, a causative role of perturbed 5-HT 6 R function between two diseases was poorly defined. In the present study, we found that a 5-HT 6 R antagonist, SB271036 rescued memory impairment by attenuating the generation of Aβ via the inhibition of γ-secretase activity and the inactivation of astrocytes and microglia in the AD mouse model. It was found that the reduction of serotonin level was significantly recovered by SB271036, which was mediated by an indirect regulation of serotonergic neurons via GABA. Selective serotonin reuptake inhibitor (SSRI), fluoxetine significantly improved cognitive impairment and behavioral changes. In human brain of depression patients, we then identified the potential genes, amyloid beta (A4) precursor protein-binding, family A, member 2 (APBA2), well known AD modulators by integrating datasets from neuropathology, microarray, and RNA seq. studies with correlation analysis tools. And also, it was demonstrated in mouse models and patients of AD. These data indicate functional network of 5-HT 6 R between AD and depression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
5HT6R antagonist reduces the formation of amyloid plaque since it reduces gamma-secretase activity without having any effect on β secretase.
“The same molecule also reduces the formation of amyloid plaque since it reduces the gamma-secretase activity without having any effect on β secretase [13].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [13]
5HT6R antagonist improves cognitive decline by enhancing serotonin levels via GABAergic neurons.
“A study reports that 5HT6R antagonist improves cognitive decline by enhancing serotonin levels via GABAergic neurons.”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 56 · Cited by 62
- Authors
- Yun, H.-M., Park, K.-R., Kim, E.-C., Kim, S., & Hong, J. T.
- Affiliations
- Kyung Hee University (KR)
- Stanley Medical Research Institute (US)
- Chungbuk National University (KR)
- Corresponding author
- Yun, Hyung-Mun
- Park, Kyung-Ran
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-22
- Volume
- 6
- Issue
- 29
- Pages
- 26716-26728
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC4694947
- OpenAlex
- W1933444002
- Cited by
- 62
- References
- 56
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 4
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- POSCO TJ Park Foundation
- National Research Foundation
- Ministry of Science, ICT and Future Planning (MRC.2008-0062275, 2012R1A5A2051384, 2008-0062275)
- National Research Foundation of Korea (MRC 2008‐0062275, 2012R1A5A2051384, 2008‐0062275)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- 5-HT6 receptor, Alzheimer's disease, depression, amyloid-beta, gamma-secretase inhibition, astrocytes, microglia, serotonergic neurons, GABA, fluoxetine, selective serotonin reuptake inhibitors, memory impairment, cognitive impairment, gene regulatory networks
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Alzheimer Disease, Amyloid, Animals, Astrocytes, Behavior, Animal, Brain, Carrier Proteins, Cognition Disorders, Depression, Disease Models, Animal, Fluoxetine, Gene Expression Regulation, Humans, Inflammation, Male, Memory Disorders, Mice, Inbred ICR, Nerve Tissue Proteins, Peptide Fragments, Receptors, Serotonin, Serotonin Antagonists, Cadherins, Amyloid beta-Peptides, Sequence Analysis, RNA, Microglia, Maze Learning, Oligonucleotide Array Sequence Analysis, Adaptor Proteins, Signal Transducing, Mice, Amyloid Precursor Protein Secretases, Serotonergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review